Phase III submission and failures in Pharma R&D

Sally Church on Pharma Strategy Blog discusses a recent article published in “Nature Reviews Drug Discovery” on Phase III drug submissions and failures between 2007 and 2010.

Phase II results are not necessarily a guarantee of phase III success in oncology as evidenced by the results for sanofi-aventis’ PARP inhibitor, iniparib in triple negative breast cancer.

Sally’s post published on Pharma Strategy Blog provides further insight and analysis.

, , , , ,

error: Content is protected !!